(secondQuint)DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO).

 Patients who receive direct-acting anti-HCV treatment will be prospectively studied during 2-year period.

 All patients have HCV/HBV co-infection.

 The inclusion/exclusion criteria and the follow up plan will be listed in following part.

.

 DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)@highlight

This is a prospective study to determine the incidence, morbidity, mortality and predisposing factors for the reactivation of hepatitis B virus replication during direct anti-HCV treatment of HCV/HBV co-infection patients.

